This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.rt.com/news/522333-eu-legal-case-astrazeneca-covid-vaccine/

The article has changed 3 times. There is an RSS feed of changes available.

Version 1 Version 2
EU seeks swift resolution as legal case against AstraZeneca over Covid vaccine supply delays begins in court EU seeks swift resolution as legal case against AstraZeneca over Covid vaccine supply delays begins in court
(about 2 months later)
The European Union’s (EU) court case against AstraZeneca has begun in a Brussels court, after the European Commission launched legal action against the pharmaceutical giant for failing to meet Covid vaccine delivery targets.The European Union’s (EU) court case against AstraZeneca has begun in a Brussels court, after the European Commission launched legal action against the pharmaceutical giant for failing to meet Covid vaccine delivery targets.
The proceedings began in the Brussels Court of First Instance on Wednesday after the EU claimed that AstraZeneca had breached an agreement to ensure that Covid vaccines ordered by the bloc were delivered in a timely manner.The proceedings began in the Brussels Court of First Instance on Wednesday after the EU claimed that AstraZeneca had breached an agreement to ensure that Covid vaccines ordered by the bloc were delivered in a timely manner.
The legal action was sparked after AstraZeneca was only able to deliver around a quarter of the 120 million doses ordered by the EU within the first quarter of 2021 due to production problems at one of its plants, delaying the vaccine rollout across Europe.The legal action was sparked after AstraZeneca was only able to deliver around a quarter of the 120 million doses ordered by the EU within the first quarter of 2021 due to production problems at one of its plants, delaying the vaccine rollout across Europe.
The EU argues that AstraZeneca failed to meet its contractual obligations after the company refused to send doses from plants in the UK to make up the European shortfall. AstraZeneca’s boss, Pascal Soriot, defended the decision to not send doses manufactured in the UK, as he said it would have violated the company’s agreement with the British government.The EU argues that AstraZeneca failed to meet its contractual obligations after the company refused to send doses from plants in the UK to make up the European shortfall. AstraZeneca’s boss, Pascal Soriot, defended the decision to not send doses manufactured in the UK, as he said it would have violated the company’s agreement with the British government.
“What matters to us in this case: There’s a speedy delivery of a sufficient number of doses that European citizens are entitled to and have been promised on the basis of the contract,” an EU spokesperson said ahead of the court case.“What matters to us in this case: There’s a speedy delivery of a sufficient number of doses that European citizens are entitled to and have been promised on the basis of the contract,” an EU spokesperson said ahead of the court case.
The case will be held under emergency procedures that will allow it to be concluded within two public hearings, meaning a decision can be made within a few weeks.AstraZeneca has rejected the accusations of the European Commission, saying it regrets that the bloc has taken the disagreement to court. The pharmaceutical company claims that the suggestion it has breached the contract is “without merit,” stating that the company will “strongly defend itself in court.”The case will be held under emergency procedures that will allow it to be concluded within two public hearings, meaning a decision can be made within a few weeks.AstraZeneca has rejected the accusations of the European Commission, saying it regrets that the bloc has taken the disagreement to court. The pharmaceutical company claims that the suggestion it has breached the contract is “without merit,” stating that the company will “strongly defend itself in court.”
If you like this story, share it with a friend!If you like this story, share it with a friend!
Dear readers and commenters,
We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.
Sorry for the inconvenience, and looking forward to your future comments,
RT Team.